SV2011003857A - Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. - Google Patents

Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.

Info

Publication number
SV2011003857A
SV2011003857A SV2011003857A SV2011003857A SV2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A
Authority
SV
El Salvador
Prior art keywords
bifenil
carboxamida
dimetil
morfolin
metoxi
Prior art date
Application number
SV2011003857A
Other languages
English (en)
Inventor
Joginder Singh Bajwa
La Cruz Marilyn De
Stephanie Kay Dodd
Liladhar Murlindar Waykole
Raeann Wu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011003857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SV2011003857A publication Critical patent/SV2011003857A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PREPARAN Y SE CARACTERIZAN SALES DE N-[6-(CIS-2,6-DIMETIL-MORFOLIN-4-IL)-PIRIDIN-3-IL]-2-METIL-4'-(TRIFLUORO-METOXI)-[1,1'-BIFENIL]-3-CARBOXAMIDA
SV2011003857A 2008-09-17 2011-03-17 Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. SV2011003857A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9758008P 2008-09-17 2008-09-17

Publications (1)

Publication Number Publication Date
SV2011003857A true SV2011003857A (es) 2011-05-16

Family

ID=41228716

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003857A SV2011003857A (es) 2008-09-17 2011-03-17 Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.

Country Status (39)

Country Link
US (3) US8063043B2 (es)
EP (1) EP2342198B1 (es)
JP (2) JP4897938B2 (es)
KR (2) KR20120015363A (es)
CN (1) CN102159570B (es)
AR (2) AR073591A1 (es)
AU (1) AU2009293444B2 (es)
BR (2) BRPI0918629B8 (es)
CA (1) CA2736751C (es)
CL (1) CL2011000551A1 (es)
CO (1) CO6351744A2 (es)
CR (1) CR20110126A (es)
CU (1) CU23860B1 (es)
DK (1) DK2342198T3 (es)
DO (1) DOP2011000082A (es)
EA (1) EA020048B1 (es)
EC (1) ECSP11010985A (es)
ES (1) ES2418485T3 (es)
GE (1) GEP20125592B (es)
HK (1) HK1156628A1 (es)
HN (1) HN2011000745A (es)
HR (1) HRP20130597T1 (es)
IL (1) IL211412A (es)
JO (1) JO2889B1 (es)
MA (1) MA32717B1 (es)
MX (1) MX2011002805A (es)
MY (1) MY151100A (es)
NI (1) NI201100051A (es)
NZ (1) NZ591420A (es)
PE (1) PE20110292A1 (es)
PL (1) PL2342198T3 (es)
PT (1) PT2342198E (es)
SI (1) SI2342198T1 (es)
SM (1) SMT201300072B (es)
SV (1) SV2011003857A (es)
TW (1) TWI367883B (es)
UA (1) UA103049C2 (es)
WO (1) WO2010033481A1 (es)
ZA (1) ZA201101579B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
WO2014128661A1 (en) 2013-02-25 2014-08-28 Novartis Ag Oral formulation and suspension of an oncology drug
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
EP3279198B1 (en) * 2015-03-30 2020-01-01 Crystal Pharmatech Co., Ltd Crystal form of n-[6-(cis form-2,6-dimethylmorpholine-4-group)pyridine-3- group]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3- formamide monophosphate, and preparation method therefor
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
KR102511024B1 (ko) 2016-03-15 2023-03-16 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060058728A (ko) * 2003-10-02 2006-05-30 파마시아 앤드 업존 캄파니 엘엘씨 피롤-치환된 인돌리논 화합물의 염 및 다형체
GB0412468D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Also Published As

Publication number Publication date
KR101129088B1 (ko) 2012-03-23
JP4897938B2 (ja) 2012-03-14
HK1156628A1 (es) 2012-06-15
DOP2011000082A (es) 2011-04-15
US20110178085A1 (en) 2011-07-21
CU23860B1 (es) 2013-02-26
AU2009293444B2 (en) 2012-03-15
CL2011000551A1 (es) 2011-07-15
HRP20130597T1 (en) 2013-07-31
EP2342198B1 (en) 2013-04-03
US20120035174A1 (en) 2012-02-09
CA2736751A1 (en) 2010-03-25
KR20120015363A (ko) 2012-02-21
MA32717B1 (fr) 2011-10-02
BRPI0918629A2 (pt) 2020-10-27
CN102159570B (zh) 2014-01-15
EP2342198A1 (en) 2011-07-13
TW201016686A (en) 2010-05-01
IL211412A (en) 2014-07-31
IL211412A0 (en) 2011-05-31
US20120214810A1 (en) 2012-08-23
JO2889B1 (en) 2015-03-15
AR113778A2 (es) 2020-06-10
GEP20125592B (en) 2012-07-25
CR20110126A (es) 2011-04-27
CA2736751C (en) 2012-10-23
TWI367883B (en) 2012-07-11
BRPI0918629B8 (pt) 2021-05-25
BR122020009045B1 (pt) 2022-08-02
NI201100051A (es) 2011-09-08
WO2010033481A1 (en) 2010-03-25
US8063043B2 (en) 2011-11-22
BR122020009045A2 (pt) 2020-11-10
CN102159570A (zh) 2011-08-17
UA103049C2 (uk) 2013-09-10
PT2342198E (pt) 2013-07-10
EA201100501A1 (ru) 2011-10-31
AU2009293444A1 (en) 2010-03-25
AR073591A1 (es) 2010-11-17
CO6351744A2 (es) 2011-12-20
NZ591420A (en) 2012-07-27
PE20110292A1 (es) 2011-05-17
SMT201300072B (it) 2013-09-06
JP2012502912A (ja) 2012-02-02
DK2342198T3 (da) 2013-07-01
HN2011000745A (es) 2014-01-06
ECSP11010985A (es) 2011-05-31
PL2342198T3 (pl) 2013-08-30
SI2342198T1 (sl) 2013-07-31
ES2418485T3 (es) 2013-08-14
BRPI0918629B1 (pt) 2021-04-13
CU20110055A7 (es) 2011-12-28
JP2012097104A (ja) 2012-05-24
MY151100A (en) 2014-04-15
EA020048B1 (ru) 2014-08-29
MX2011002805A (es) 2011-04-11
KR20110056325A (ko) 2011-05-26
ZA201101579B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
SV2011003857A (es) Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
EA201170227A1 (ru) Имидазолкарбоксамиды
UY30600A1 (es) Compuestos novedosos
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
PA8667201A1 (es) Nuevos compuestos farmaceuticos
EA201270149A1 (ru) Ингибиторы bace
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
TW201713640A (en) Bruton's tyrosine kinase inhibitors
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CR11861A (es) Compuestos organicos
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
UY34013A (es) ?compuestos de cromenona con actividad anti-tumoral?.
UY31688A1 (es) Plaguicidas
UA106880C2 (uk) Нові гербіциди
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
EA201290642A1 (ru) Соединения и способы
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
UY33976A (es) Derivados de pirazolo-pirimidina.